Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2006; 12(8): 1265-1269
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1265
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1265
Table 4 Summary of adverse events n (%)
| Triple therapy group | Dual therapy group | ||
| Fever | 35 (89.7) | 38 (97.4) | NS |
| Anorexia | 26 (66.7) | 25 (64.1) | NS |
| Fatigue | 24 (61.5) | 22 (59.0) | NS |
| Arthralgia | 20 (51.3) | 18 (46.1) | NS |
| Eczema | 16 (41.0) | 13 (33.3) | NS |
| Nausea | 14 (35.9) | 13 (33.3) | NS |
| Abdominal discomfort | 8 (20.5 ) | 18 (46.2) | P < 0.019 |
| Stomatitis | 13 (33.3) | 12 (30.8) | NS |
| Headache | 11 (28.2) | 14 (35.9) | NS |
| Hair loss | 12 (30.8) | 7 (17.9) | NS |
| Psychosomatic | 3 (7.7) | 1 (2.6) | NS |
- Citation: Suzuki H, Takagi H, Sohara N, Kanda D, Kakizaki S, Sato K, Mori M. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: A randomized controlled clinical trial. World J Gastroenterol 2006; 12(8): 1265-1269
- URL: https://www.wjgnet.com/1007-9327/full/v12/i8/1265.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i8.1265